
Personalised mRNA vaccine plus Keytruda halts melanoma relapse in trial
A phase 3 trial of a personalised mRNA vaccine (Intismeran) given with Keytruda after melanoma surgery extended disease-free time in over 1,000 high-risk patients. While the interim results are promising, they have not yet been peer-reviewed and regulatory approval is still required before NHS rollout.
